Financial engineering for good: A new approach to funding large-scale biomedical innovation

There is a growing consensus that the “bench-to-bedside” process of translating biomedical  research into effective therapeutics is broken. A confluence of factors explains such pessimism but among the most widespread is the sense that the current the drug development business model is flawed. The development of new therapeutics